Highlight of this talk

In this session there is discussion of one of the group from each of

• DPP4-inhibitors (gliptins, incretin- mimetic)
• GLP-1 ( glucagon -like-peptide -1,incretin-mimetic)
• SGLT-2 inhibitors ( sodium- glucose cotransporter-2 inhibitor, gliflozin)

Learning outcome:
to contextualise pharmaceutical knowledge to optimise health for diabetic patients

Speaker

Dr Saqib Mahmud
FRCP(Edin); FRCP(Glasg); FRCP(London); FRCGP
Primary care physician, GP trainer and GPwSI in Diabetes and Cardiology

Chairperson

Dr Jane Wilcock
BSc MBChB FRCGP PGCertMedEd, MA HEd and SF HEA
GP, Clinical advisor RCGP, Chair overdiagnosis group RCGP, Vicechair NWE faculty RCGP

Awarded 1 CPD Credit